Clinical trials using MAF for hospitalized COVID-19 patients
The clinical trial using MAF capsules has started in Kazakhstan for the patients suffering with coronavirus aftereffects in February 2021.
The clinical trial using MAF capsules has started in Italy from November for hospitalised patients with COVID-19.
Saisei Pharma plans clinical study of oral MAF in COVID-19 patients
Clinical trial to evaluate oral MAF, macrophage activating factor, in the prevention of the COVID-19 associated cytokine storm and the role of macrophages as a front-line innate immunity defense is announced.
A cytokine storm is a type of severe immune overreaction that could result from the novel coronavirus infection and may contribute to acute respiratory disease which has life-threatening complications in patients with COVID-19.
“Our innate immunity can fight off pathogens without causing inflammation and associated respiratory deterioration.”
Wheat, soy, egg, rice, gluten, starch, sugar (excluding M-Lollies), hormones, antibiotics, preservatives, artificial sweeteners, artificial colours.
Easy to take
We have created 2 types of MAF products to cover many areas such as mouth, gut and skin.
Very unique MAF
We have developed our very own unique MAF (macrophage activating factor) using our patented method. MAF helps boost the immune system by activating macrophages without any side effects.
Produced in GMP Certified factory in Japan
MAF Series products are produced in our Saisei Mirai GMP Certified factory (Certification No. 26518) in Moriguchi, Osaka, certified by the Ministry of Health, Labor and Welfare of Japan.
Saisei Mirai Group
We have partnered with 5 domestic clinics in Japan which are based on Saisei Mirai Medical Corporation, bio-venture companies, pharmacies, and universities and medical institutions in Japan and overseas, and have started providing advanced medical care worldwide.